A New Era in Heart & Metabolic Health

  • Blogs

A New Era in Heart & Metabolic Health

Over the past few years, injectable medications like Ozempic, Wegovy, and Mounjaro
have revolutionised how we approach weight loss and type 2 diabetes.

But beyond blood sugar and body weight, these treatments are now being recognised for something far more significant — their ability to protect the heart
.

At The Wright Practice
in Harley Street, we focus on proactive and longevity-based healthcare
. Understanding how these medicines work — and who they benefit most — helps us tailor truly individual health plans.

Ozempic® (Semaglutide 0.5–1.0 mg weekly): Diabetes and Heart Protection

Ozempic was originally developed for type 2 diabetes, but large studies have shown it lowers the risk of serious heart events
such as heart attack and stroke.

The evidence:

The SUSTAIN-6
trial (published in the New England Journal of Medicine) found that people with type 2 diabetes taking Ozempic had:

  • 25% fewer major cardiovascular events
    than those on placebo
  • Fewer non-fatal strokes and heart attacks
  • Benefits that appeared within the first year and strengthened over time

✅ Takeaway:
Ozempic not only helps regulate blood sugar and support weight management — it also protects against cardiovascular disease
in those already at risk.

Wegovy® (Semaglutide 2.4 mg weekly): Heart Protection Without Diabetes

Wegovy, which contains the same active ingredient as Ozempic but at a higher dose, is prescribed for weight management.

Until recently, no weight-loss medicine had been proven to actually reduce the risk of heart attack or stroke
. That changed with the landmark SELECT trial (2023)
.

The evidence:

  • Over 17,000 adults with obesity (BMI ≥27) and established heart disease but no diabetes
    were studied.
  • Those taking Wegovy had a 20% lower risk of major heart events
    (heart attack, stroke, or heart-related death).
  • Benefits extended beyond weight loss — participants also saw improvements in blood pressure, cholesterol, and inflammation.

✅ Takeaway:
Wegovy is now the first weight-loss medication approved by the FDA to reduce cardiovascular risk
. For patients with heart disease and excess weight, this is a major step forward in preventive medicine.

Mounjaro® (Tirzepatide): Dual Hormone Innovation

Mounjaro is slightly different — it acts on both GLP-1 and GIP receptors
, offering powerful effects on glucose control and weight reduction.

The evidence so far:

The ongoing SURPASS-CVOT
study compared Mounjaro with dulaglutide (another GLP-1 medicine). Early data suggest:

  • Mounjaro is at least as safe for the heart
    as dulaglutide
  • There may be a trend toward fewer heart events, but full results are still being analysed

✅ Takeaway:
Mounjaro already appears heart-safe
, and upcoming data may confirm additional cardiovascular benefits similar to semaglutide.

What This Means for You

These medicines aren’t simply about appearance or numbers on a scale.
They’re part of a whole-body, heart-protective strategy
that can:

  • Reduce inflammation and oxidative stress
  • Improve insulin sensitivity
  • Lower blood pressure and cholesterol
  • Support sustainable, long-term cardiovascular health

At The Wright Practice
, we integrate these treatments as part of a comprehensive longevity plan
— including nutrition, exercise, hormone optimisation, and advanced blood testing.

In Summary

MedicationMain StudyWho It HelpedHeart ImpactOzempic®
SUSTAIN-6Type 2 diabetes↓ 25% heart attacks, strokes, CV deathsWegovy®
SELECTObesity + CVD (no diabetes)↓ 20% major heart events (FDA-approved)Mounjaro®
SURPASS-CVOTType 2 diabetesHeart-safe, results pending

The Wright Practice Approach

We believe in treating the whole person
, not just one marker.
Whether your goal is longevity, weight optimisation, or cardiovascular prevention, our personalised approach combines the best of modern medical science and lifestyle medicine.

Book a consultation
to discuss whether a GLP-1 or GIP treatment could support your long-term health goals.

Meet our team

Dr Daniel Wright
MD MRCGP MA BA (Hons)
Meet Dr Daniel Wright
Susan Jain
Dr Susan Jain
BSc MB BS MRCP FRCA FFICM
Meet Dr Susan Jain
Nathan Hunt
Nathan Hunt
Practice Manager
Meet Nathan Hunt
Tamara
Tamara Golstein
Naturopath & Nutritional Therapist
Meet Tamara Golstein

The Wright Practice

101 Harley Street, London, W1G 6AH, United Kingdom

Rated ★ ★ ★ ★ ★ from 197 Reviews

Opening hours
Monday
9.00 - 17.00
Tuesday
9.00 - 17.00
Wednesday
9.00 - 17.00
Thursday
9.00 - 17.00
Friday
9.00 - 17.00
Saturday
9.00 - 17.00
Sunday
Closed
The Wright Practice
101 Harley Street, London, W1G 6AH, United Kingdom
Get directions
Book Online
Whatsapp